AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:02:29 28/06/2024 BST			5-day change	1st Jan Change
171.5 ^USD	+1.50%		+0.66%	+10.68%

06-28	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT
06-28	AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	MT

AbbVie Inc. acquired Celsius Therapeutics, Inc. for $250 million.

June 26, 2024

AbbVie Inc. (NYSE:ABBV) acquired Celsius Therapeutics, Inc. for $250 million on June 27, 2024. Covington & Burling LLP acted as legal advisor for AbbVie Inc. Centerview Partners LLC acted as financial advisor for Celsius Therapeutics, Inc. Goodwin Procter LLP acted as legal advisor for Celsius Therapeutics, Inc.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Celsius Therapeutics, Inc. on June 27, 2024.

Latest news about AbbVie Inc.

Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	06-28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	06-28	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	06-27	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	06-27	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	06-27	MT
AbbVie: acquisition of Celsius for $250 million	06-27	CF
AbbVie Buys Celsius Therapeutics for $250 Million	06-27	DJ
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal	06-27	MT
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	06-27	MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	06-27	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	06-27	CI
AbbVie Inc. acquired Celsius Therapeutics, Inc. for $250 million.	06-26	CI
AbbVie Gets New FDA Accelerated Approval for Epkinly	06-26	DJ
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo -- Update	06-25	DJ
AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease	06-25	MT
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo	06-25	DJ
US FDA declines to approve AbbVie's Parkinson's disease therapy	06-25	RE
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	06-25	CI
AbbVie Keeps Quarterly Dividend at $1.55 per Share, Payable Aug. 15 to Shareholders of Record July 15	06-21	MT
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024	06-21	CI
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis	06-20	MT
US FDA proposes to remove switching study requirement for biosimilars	06-20	RE

Chart AbbVie Inc.

Duration

Period

More charts

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

14/07/2024 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

171.5 USD

Average target price

183.2 USD

Spread / Average Target

+6.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+10.68%	303B
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B
SANOFI	+0.20%	120B

Other Pharmaceuticals

AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

AbbVie Inc. acquired Celsius Therapeutics, Inc. for $250 million.

EPS Revisions